Skip to content

Umbilical Cord Mesenchymal Stem Cell Secretome Administration in Severe Erectile Dysfunction Non-responsive to Sildenafil

Analysis of the Safety and Efficacy of Administering Umbilical Cord Mesenchymal Stem Cell Secretome in Patients With Severe Erectile Dysfunction Non-responsive to Sildenafil

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07245875
Enrollment
12
Registered
2025-11-24
Start date
2024-04-12
Completion date
2025-08-01
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus Type 2, Erectile Dysfunction

Keywords

erectile dysfunction, non responsive to sildenafil, secretome, Umbilical Cord Mesenchymal Stem Cell

Brief summary

The study is an experimental pre-post-test design involving 12 patients with severe ED non-responsive to sildenafil. Safety parameters included pain, hematoma, local bleeding, and infection, while efficacy was measured using the IIEF-5 questionnaire, EHS, and morning erection.

Detailed description

The study employed umbilical cord mesenchymal stem cell secretome, one intravenous injection containing one ml into two locations, one injection in one cavernous body, and three direct follow-ups with the patient: directly after injection, one day and one month after the injection.

Interventions

BIOLOGICALIntracavernosal Injection of Umbilical Cord Mesenchymal Stem Cell Secretome

UC-MSC secretome was obtained from UC-MSC cultures with 80% confluence in serum-free medium after 24 hours of incubation The VEGF level in the secretome given was 1400 pg/ml. The intervention was the administration of 0.5 mL/site of secretome injection injected intra-cavernous to all subjects using a 22-gauge needle according to a sterile protocol. The same volume was given at bilateral sites of the penile shaft. The intra-cavernous injection sites were in the right and left dorsolateral regions of the penis. After the intervention, tolerability was assessed by observing and questioning the subjects regarding pain during injection.

Sponsors

Indonesia University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
40 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Men aged 40-65 years who undergo treatment at the Andrology Clinic of RSUD Dr. Soetomo. * Severe erectile dysfunction caused by organic factors for at least 6 months, based on an IIEF-5 score of 5-7 * History of undergoing treatment with sildenafil 100 mg for four sessions. * Evaluation of IIEF-5 score \< 22 and not meeting the MCID criteria, defined as an IIEF-5 score increase of less than 4 * Type II Diabetes Melitus with an HbA1c test result of \< 7%. * Laboratory test results for liver function (SGOT and SGPT) and kidney function (urea and creatinine) are within normal limits. * Patients with undergoing treatment with antidepressant.

Exclusion criteria

* Anatomical abnormalities of the penis that are clinically visible, such as Peyronie's disease, a history of priapism, a history of penile implants, skin irritation, and lesions in the area surrounding the penile skin. * Active and significant systemic or local infection. * History of bleeding or blood clotting disorder therapy. * History of systemic autoimmune disorders and immunosuppressive treatment * History of prostate surgery, history of malignancy, or a PSA level \> 4 ng/mL. * Untreated hypogonadism or low serum total testosterone (\<200 ng/dL). * Uncontrolled hypertension or hypotension (systolic blood pressure \>170 or \<90 mmHg, and diastolic blood pressure \>100 or \<50 mmHg). * Unstable cardiovascular disease (e.g., unstable angina, myocardial infarction within the last 6 months, and congestive heart failure).

Design outcomes

Primary

MeasureTime frameDescription
Visual Analog Scaleone day and one monthA visual analog is used for measuring pain. The patient will be asked to describe the pain on scale 1 to 10. Scale 1 means no pain and 10 means very great pain. A higher score indicates a worse outcome.
Hematomesone day and one monthHematomes means blue discoloration. 0 scale means ther is no discoloration and 1 means there is discoloration.
Bleedingone day and one monthBleeding is one of the outcomes of the research. If there is bleeding, it would be marked as 1; if there is no bleeding, it would be marked as 0.
Erection Hardness ScoreOne monthRapid diagnostic tool to evaluate erectile dysfunction. There are 4 scores. 1 indicate severe erectile dysfunction (worst) and 4 indicates there is optimal erection (good).
IIEF-5One monthRapid diagnostic tool to evaluate erectile dysfunction
Restrictive Indexone month
PSVone month
SPLone month
FPLone month
Penile Circumferenceone month

Countries

Indonesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026